Biogen posts 50% growth in profits

Biogen Idec's first-quarter profits jumped 50 percent to $244 million on higher sales of its multiple sclerosis drug Avonex; revenues grew by a healthy 10 percent to $1.04 billon, and EPS beat analysts' estimates. Report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.